Axsome Therapeutics, week twelve prescriptions for Auvelity, is the second week of a new quarter of revenue, for the companies recently approved MDD drug. These first two weeks of the first quarter of 2023 will also start the first complete, 12 week quarter for Auvelity since approval. The launch is off to a good start. Stats from IQVIA.
Week 11 01/06/23 = 1300
Week 12 01/13/23 = 1650
No comments:
Post a Comment